Jasper Therapeutics Reports First Patient Dosing with Briquilimab in P-Ib/IIa Trial for Treating Chronic Inducible Urticaria
Shots:
- Jasper Therapeutics has dosed the first patient with briquilimab in the P-Ib/IIa clinical evaluation for treating chronic inducible urticaria (CIndU)
- The P-Ib/IIa (SPOTLIGHT) trial assesses the safety, efficacy, PK characteristics & tolerability of briquilimab (SC) single administration at two different dose levels for the treatment of patients (n=~15) with cold urticaria (ColdU) or symptomatic dermographism (SD) across the EU. The preliminary results are expected in H2’24
- Briquilimab (formerly JSP191) is a targeted aglycosylated mAb that inhibits the binding of stem cell factor with the cell-surface receptor c-Kit (CD117), blocking receptor signaling
Ref: Jasper Therapeutics | Image: Jasper Therapeutics
Related News:- BioLineRx Reports First Patient Dosing with Motixafortide in P-II Study for the Treatment of Pancreatic Cancer (PDAC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
